Glycorex Transplantation AB (NGM:GTAB B) Shares Outstanding (EOP): 78.85 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:GTAB B Glycorex Transplantation AB NGM:GTAB B
61 GF Score
Price kr1.46
GF Value kr1.81
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Glycorex Transplantation AB Shares Outstanding (EOP)?

Glycorex Transplantation AB NGM:GTAB B -8.75% 61 Shares Outstanding (EOP) is 78.85 Mil as of Mar. 2026. GuruFocus rates NGM:GTAB B with a GF Score™ of 61/100 and a GF Value™ of kr1.81 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Glycorex Transplantation AB's shares outstanding for the quarter that ended in Mar. 2026 was 78.85 Mil.

Glycorex Transplantation AB's quarterly shares outstanding stayed the same from Dec. 2025 (78.85 Mil) to Mar. 2026 (78.85 Mil).

Glycorex Transplantation AB's annual shares outstanding increased from Dec. 2024 (73.85 Mil) to Dec. 2025 (78.85 Mil). It means Glycorex Transplantation AB issued new shares from Dec. 2024 to Dec. 2025 .


Glycorex Transplantation AB  (NGM:GTAB B) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Glycorex Transplantation AB Shares Outstanding (EOP) Related Terms


Glycorex Transplantation AB Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Glycorex Transplantation AB's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glycorex Transplantation AB Shares Outstanding (EOP) Chart

Glycorex Transplantation AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.85 73.85 73.85 73.85 78.85

Glycorex Transplantation AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.12 78.85 82.12 78.85 78.85

NGM:GTAB B vs VRTX, REGN, RVMD: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Glycorex Transplantation AB's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glycorex Transplantation AB Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Glycorex Transplantation AB's Shares Outstanding (EOP) falls into.


NGM:GTAB B
61GF Score
Glycorex Transplantation AB NGM:GTAB B
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glycorex Transplantation AB Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 78.85 Mil mean?
Glycorex Transplantation AB (NGM:GTAB B) has a Shares Outstanding (EOP) of 78.85 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Glycorex Transplantation AB and its competitors.
Is Glycorex Transplantation AB's Shares Outstanding (EOP) too high?
Glycorex Transplantation AB's current Shares Outstanding (EOP) is 78.85 Mil. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Shares Outstanding (EOP) compare to VRTX and REGN?
Glycorex Transplantation AB's Shares Outstanding (EOP) of 78.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Glycorex Transplantation AB and its competitors. Glycorex Transplantation AB's current Shares Outstanding (EOP) is 78.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (NGM:GTAB B) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.81, compared to a current price of kr1.46 — trading 19.3% below its estimated fair value. The current Shares Outstanding (EOP) is 78.85 Mil. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Glycorex Transplantation AB (NGM:GTAB B), the current Shares Outstanding (EOP) is 78.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glycorex Transplantation AB (NGM:GTAB B) Overvalued in 2026?

Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued. The current stock price of kr1.46 is trading 19.3% below its estimated GF Value™ of kr1.81. GuruFocus considers Glycorex Transplantation AB to be Modestly Undervalued.

Key valuation signals for NGM:GTAB B:

  • Shares Outstanding (EOP): 78.85 Mil
  • GF Value™: kr1.81 vs. price of kr1.46 (19.3% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NGM:GTAB B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glycorex Transplantation AB Business Description

Other Exchanges O33:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score

Get the complete analysis for NGM:GTAB B

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.46
Price
kr1.81
GF Value